194 related articles for article (PubMed ID: 28140338)
1. A Monte Carlo study of I-125 prostate brachytherapy with gold nanoparticles: dose enhancement with simultaneous rectal dose sparing via radiation shielding.
Brivio D; Nguyen PL; Sajo E; Ngwa W; Zygmanski P
Phys Med Biol; 2017 Mar; 62(5):1935-1948. PubMed ID: 28140338
[TBL] [Abstract][Full Text] [Related]
2. Comparison of seed loading approaches in prostate brachytherapy.
Butler WM; Merrick GS; Lief JH; Dorsey AT
Med Phys; 2000 Feb; 27(2):381-92. PubMed ID: 10718143
[TBL] [Abstract][Full Text] [Related]
3. Minimizing the number of implantation needles for prostate (125)I brachytherapy: an investigation of possibilities and implications.
Steggerda MJ; van der Poel HG; Moonen LM
Brachytherapy; 2010; 9(4):319-27. PubMed ID: 20691644
[TBL] [Abstract][Full Text] [Related]
4. Large-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy.
Miksys N; Vigneault E; Martin AG; Beaulieu L; Thomson RM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):606-615. PubMed ID: 28126308
[TBL] [Abstract][Full Text] [Related]
5. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
[TBL] [Abstract][Full Text] [Related]
6. A radiobiology-based inverse treatment planning method for optimisation of permanent l-125 prostate implants in focal brachytherapy.
Haworth A; Mears C; Betts JM; Reynolds HM; Tack G; Leo K; Williams S; Ebert MA
Phys Med Biol; 2016 Jan; 61(1):430-44. PubMed ID: 26675313
[TBL] [Abstract][Full Text] [Related]
7. Monte Carlo simulation of radiation transport and dose deposition from locally released gold nanoparticles labeled with
Lai P; Cai Z; Pignol JP; Lechtman E; Mashouf S; Lu Y; Winnik MA; Jaffray DA; Reilly RM
Phys Med Biol; 2017 Oct; 62(22):8581-8599. PubMed ID: 29077574
[TBL] [Abstract][Full Text] [Related]
8. [Permanent implant prostate cancer brachytherapy: 2013 state-of-the art].
Cosset JM; Hannoun-Lévi JM; Peiffert D; Delannes M; Pommier P; Pierrat N; Nickers P; Thomas L; Chauveinc L
Cancer Radiother; 2013 Apr; 17(2):111-7. PubMed ID: 23478488
[TBL] [Abstract][Full Text] [Related]
9. Interstitial rotating shield brachytherapy for prostate cancer.
Adams QE; Xu J; Breitbach EK; Li X; Enger SA; Rockey WR; Kim Y; Wu X; Flynn RT
Med Phys; 2014 May; 41(5):051703. PubMed ID: 24784369
[TBL] [Abstract][Full Text] [Related]
10. Gold nanoparticle-based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye.
Asadi S; Vaez-zadeh M; Masoudi SF; Rahmani F; Knaup C; Meigooni AS
J Appl Clin Med Phys; 2015 Sep; 16(5):344–357. PubMed ID: 26699318
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric comparison of interactive planned and dynamic dose calculated prostate seed brachytherapy.
Meijer GJ; van den Berg HA; Hurkmans CW; Stijns PE; Weterings JH
Radiother Oncol; 2006 Sep; 80(3):378-84. PubMed ID: 16930753
[TBL] [Abstract][Full Text] [Related]
12. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
13. Dose perturbation effects in prostate seed implant brachytherapy with I-125.
Mobit P; Badragan I
Phys Med Biol; 2004 Jul; 49(14):3171-8. PubMed ID: 15357190
[TBL] [Abstract][Full Text] [Related]
14. Investigation of interseed attenuation and tissue composition effects in (125)I seed implant prostate brachytherapy.
Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
Brachytherapy; 2014; 13(6):603-10. PubMed ID: 24913435
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the relationship between prescribed dose and dosimetric advantage of real-time intraoperatively built custom-linked seeds in iodine-125 prostate brachytherapy.
Hirose K; Aoki M; Sato M; Akimoto H; Hashimoto Y; Imai A; Kamimura N; Kawaguchi H; Hatayama Y; Fujioka I; Tanaka M; Ohyama C; Takai Y
Radiat Oncol; 2017 Dec; 12(1):192. PubMed ID: 29191234
[TBL] [Abstract][Full Text] [Related]
17. Prostatic conformal brachytherapy: 125I/103Pd postoperative dosimetric analysis.
Merrick GS; Butler WM; Dorsey AT; Walbert HL
Radiat Oncol Investig; 1997; 5(6):305-13. PubMed ID: 9436248
[TBL] [Abstract][Full Text] [Related]
18. [Intraoperative and post-implant dosimetry in patients treated with permanent prostate implant brachytherapy].
Herein A; Ágoston P; Szabó Z; Jorgo K; Markgruber B; Pesznyák C; Polgár C; Major T
Magy Onkol; 2015 Jun; 59(2):148-53. PubMed ID: 26035163
[TBL] [Abstract][Full Text] [Related]
19. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract][Full Text] [Related]
20. Inverse automated treatment planning with and without individual optimization in interstitial permanent prostate brachytherapy with high- and low-activity 125I.
Pinkawa M; Maurer U; Mulhern A; Gagel B; Block T; Borchers H; Grieger J; Henkel T; Eble M
Strahlenther Onkol; 2003 Jun; 179(6):417-22. PubMed ID: 12789469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
